House of Diagnostics (HOD), an integrated diagnostics platform focused on building a network of high-quality radiology and pathology centres, has secured a minority investment from 360 ONE Asset, one of India’s leading alternative asset management firms.
The investment is aimed at supporting the company’s next phase of growth, including geographic expansion, enhancement of clinical and digital infrastructure, and scaling of its consumer-led diagnostics services across pathology, radiology, and nuclear medicine.
Founded by Dr Shubham Sogani and Labham Sogani, House of Diagnostics has emerged as one of the leading integrated diagnostic networks in North India. The company operates a hybrid model built around walk-in diagnostic centres, home sample collection, and digitally enabled patient journeys. HOD currently runs 12 integrated diagnostic centres, supported by over 200 collection centres and home collection services, offering faster turnaround times and transparent pricing for consumers.
The platform has played a key role in advancing the direct-to-patient diagnostics model in North India, reducing reliance on referral-driven diagnostics. Its operating model emphasises patient experience, high-quality reporting, advanced diagnostic infrastructure, and comparatively lower pricing. HOD offers a comprehensive portfolio that includes advanced imaging services such as MRI, CT, and PET-CT, alongside high-end pathology services supported by in-house technology.
House of Diagnostics also operates one of India’s largest dry-chemistry automated laboratories and a centralised radiology reporting engine, enabling consistency, efficiency, and quality control across its network. The company plans to deploy the newly raised capital to expand into major Tier I markets, starting with Mumbai, followed by cities such as Hyderabad and Bengaluru. These markets are expected to see growing demand from digitally savvy consumers seeking transparent pricing, faster reporting, and technology-enabled diagnostic care.
For 360 ONE Asset, the investment aligns with its broader healthcare strategy focused on consumer-facing healthcare platforms with scalable, patient-centric business models. The firm views diagnostics as a rapidly evolving segment where speed, transparency, accuracy, and technology integration are increasingly influencing patient choice.
With this investment, House of Diagnostics aims to accelerate its transition into a nationally scaled diagnostics platform while strengthening governance structures and operational resilience.
The company is positioning itself as a public market–ready diagnostics brand, with a strong focus on B2C engagement, integrated diagnostics delivery, and consistent patient experience across markets.
